After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports ...

The company has promoted an insider following the departure of an executive who'd held the post for just 16 months.

In the latest close session, Novavax (NVAX) was down 4.18% at $8.95. This change lagged the S&P 500's daily loss of 1.74%.

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, ...

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Shares of Novavax Inc. NVAX shed 3.99% to $7.70 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.18% to 21,879.18 ...